News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer

11 August 2022

Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01

23 June 2022

OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021

25 March 2022

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

11 March 2022

OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board  

31 January 2022

OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer

27 January 2022

Sign up for the latest News & Events

Events & Presentations

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018

EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018

17 September 2018
This site is registered on wpml.org as a development site.